Background Patients with rheumatoid arthritis (RA) have a systemic Th1 defect associated with inflammation. Objective To examine the hypothesis that interleukin 17 (IL-17) contributes to this defect. Methods IL-17 effects on Th1 markers were examined on T-bet and interferon γ (IFNγ) expression in peripheral blood mononuclear cells (PBMCs) from patients with RA or healthy controls (HC). Receptor specificities were determined by analysis of the Th1-specific IL-12 receptor β2 (IL-12Rβ2), Th17-specific IL-23R and the common IL-12Rβ1 chain expression. Effects of IL-17 or IFNγ on IL-6, IL-1, IL-8, matrix metalloproteinase-8 (MMP-8) were measured by real-time RT-PCR in RA synovial cells. Results RA PBMCs were less responsive to IL-12-induced IFNγ than HC PBMCs. IL-12 hyporesponsiveness was increased by IL-17 treatment associated with a selective reduction in IL-12Rβ2, but not IL-23R, IL-12Rβ1 or T-bet, which was reversed with IL-17R inhibition. IL-17 inhibited IL-12Rβ2 expression in developing Th1 cells. In RA synovial cells, IL-17 induced IL-6, IL-1, IL-8 and MMP-8, whereas IFNγ haBackground Patients with rheumatoid arthritis (RA) have a systemic Th1 defect associated with inflammation. Objective To examine the hypothesis that interleukin 17 (IL-17) contributes to this defect. Methods IL-17 effects on Th1 markers were examined on T-bet and interferon γ (IFNγ) expression in peripheral blood mononuclear cells (PBMCs) from patients with RA or healthy controls (HC). Receptor specificities were determined by analysis of the Th1-specific IL-12 receptor β2 (IL-12Rβ2), Th17-specific IL-23R and the common IL-12Rβ1 chain expression. Effects of IL-17 or IFNγ on IL-6, IL-1, IL-8, matrix metalloproteinase-8 (MMP-8) were measured by real-time RT-PCR in RA synovial cells. Results RA PBMCs were less responsive to IL-12-induced IFNγ than HC PBMCs. IL-12 hyporesponsiveness was increased by IL-17 treatment associated with a selective reduction in IL-12Rβ2, but not IL-23R, IL-12Rβ1 or T-bet, which was reversed with IL-17R inhibition. IL-17 inhibited IL-12Rβ2 expression in developing Th1 cells. In RA synovial cells, IL-17 induced IL-6, IL-1, IL-8 and MMP-8, whereas IFNγ ha
廈門(mén)侖昌碩生物科技有限公司集研發(fā)、生產(chǎn)、銷(xiāo)售、服務(wù)及品牌代理為一體的生物技術(shù)公司，目前可提供各種抗體、免疫學(xué)相關(guān)的檢測(cè)試劑盒、胎牛血清，動(dòng)物抗血清等高品質(zhì)產(chǎn)品及服務(wù)，涵蓋分子生物學(xué)、細(xì)胞生物學(xué)、免疫學(xué)等生命科學(xué)領(lǐng)域。
公司非常注重企業(yè)信息化的建設(shè)及企業(yè)平臺(tái)的建設(shè)，我們內(nèi)部采用了*的信息處理平臺(tái)，保證客戶的需求可以準(zhǔn)確、高效處理。
公司成立之初，立足外貿(mào)，和部分歐美及亞非國(guó)家的客戶建立了良好的合作，隨著國(guó)內(nèi)生物領(lǐng)域的蓬勃發(fā)展，逐步把重心轉(zhuǎn)移到國(guó)內(nèi)來(lái)，為每一位科研人員獻(xiàn)上高品質(zhì)的產(chǎn)品及服務(wù)是我們的使命。
集研發(fā)、生產(chǎn)、銷(xiāo)售、服務(wù)及品牌代理為一體的生物技術(shù)公司，目前可提供各種抗體、免疫學(xué)相關(guān)的檢測(cè)試劑盒、胎牛血清，動(dòng)物抗血清等高品質(zhì)產(chǎn)品及服務(wù)，涵蓋分子生物學(xué)、細(xì)胞生物學(xué)、免疫學(xué)等生命科學(xué)領(lǐng)域。
| 產(chǎn)地 | 國(guó)產(chǎn) | 級(jí)別 | 其他 |
|---|
人白介素1β轉(zhuǎn)換酶（ICE）elisa試劑盒 產(chǎn)品信息
同類(lèi)產(chǎn)品推薦
- 面議在線詢價(jià)
- 面議在線詢價(jià)
- ￥5000在線詢價(jià)
- 面議在線詢價(jià)
- ￥1547在線詢價(jià)
Axiom™ Genotyping Services, Human Cust
面議在線詢價(jià)
產(chǎn)品名稱(chēng)參考價(jià)
在找 人白介素1β轉(zhuǎn)換酶（ICE）elisa試劑盒 產(chǎn)品的人還在看
采購(gòu)中心
